A significant correlation between melatonin deficiency and endometrial cancer

Area of Science:

• Gynecologic Oncology
• Endocrinology
• Cancer Biomarkers

Background:

• Endometrial cancer is the most common gynecologic malignancy in women, with increasing incidence.
• Current screening and diagnostic methods for endometrial cancer lack sufficient sensitivity, specificity, or are invasive.
• There is a critical need for a non-invasive and reliable screening tool for early endometrial cancer detection.

Purpose of the Study:

• To investigate potential new screening parameters for endometrial cancer.
• To evaluate plasma melatonin levels as a potential biomarker for endometrial cancer detection.

Main Methods:

• A multicenter study involving 138 women was conducted in Austria.
• Participants were selected based on risk factors, including anamnestic, serologic, and cytologic data.
• Plasma melatonin levels were measured and compared between women with endometrial cancer (n=68) and those with abnormal bleeding (n=70).

Main Results:

• A significant inverse correlation was found between plasma melatonin levels and the presence of endometrial cancer (p < 0.001).
• Mean plasma melatonin levels were substantially lower in the endometrial cancer group (6.1 pg/ml) compared to the control group (33.2 pg/ml), a six-fold difference.
• No significant differences were observed in age, menopausal status, or prevalence of comorbidities between the groups.

Conclusions:

• Decreasing plasma melatonin levels may serve as a sensitive indicator for endometrial cancer.
• Melatonin plasma levels show promise as a novel, reliable screening parameter for early endometrial cancer detection.
• Further research is warranted to validate melatonin as a screening tool in larger cohorts.